All In Biotech

Drug Trial Radar · NCT07747480

A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis

A Phase 1b, Non-Randomized, Open-Label, Repeat-Dose, Single Center Study to Investigate the Safety and Tolerability of Aletekitug in Advanced Therapy Naïve Participants With Moderate to Severe Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Mar 5, 2028

Study completion Mar 5, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.

Conditions

  • Colitis, Ulcerative

Interventions

  • AletekitugBiological

    Aletekitug will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse events (AEs)Time frame: Up to 34 weeks [End of sub-study (EOSS)]
  2. Number of Participants with Serious AEs (SAEs)Time frame: Up to 34 weeks (EOSS)
  3. Number of Participants who Discontinue Study Intervention due to AEsTime frame: Up to 34 weeks (EOSS)
  4. Number of Participants with Clinically Significant Changes in Laboratory ReadingsTime frame: Up to 34 weeks (EOSS)
  5. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to 34 weeks (EOSS)
  6. Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) ReadingsTime frame: Up to 34 weeks (EOSS)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.